February 06, 2015
Myriad Genetics Inc. on Friday settled patent infringement litigation with Quest Diagnostics Inc., dismissing claims in Utah federal court alleging Quest infringed Myriad's patents for BRCA cancer gene testing, some of which had been recently invalidated by the Federal Circuit.
January 26, 2015
Three of the seven companies that Myriad Genetics Inc. has accused of infringing its patents on breast cancer tests — Pathway Genomics Corp., Invitae Corp. and Laboratory Corporation of America Holdings — reached settlements with the molecular diagnostic company on Friday.
March 11, 2014
A Utah federal judge on Monday halted Myriad Genetics Inc.'s quest to block sales of Ambry Genetics Corp. cancer-testing products it claims infringe several of its patents, including five tackled in a landmark U.S. Supreme Court decision last year, ruling that Ambry had raised sufficient questions about the patents' validity.